LONDON--(BUSINESS WIRE)--A notable trend in recent years within the global clinical trials market has been the shift towards conducting trials in emerging economies, according to a new report available on companiesandmarkets.com.
Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)
Factors driving growth in the clinical trial market include the trend for globalization of drug development activities. R&D for therapeutic treatments is incredibly expensive and time consuming, therefore pharmaceutical companies are constantly seeking ways of cutting costs and speeding up the process. By establishing a presence away from the developed regions, companies can take advantage of lower labour, infrastructure and energy costs.
The pharmaceutical giants are also keen to exploit the large heterogeneous patient pools in emerging regions, benefiting further from the high incidence of previously untreated diseases.
Another factor in moving clinical trial activities from the developed world to the emerging economies is the difference in time taken to approve clinical trials, and to get drugs to market. Furthermore, in India for example, patent laws have become more stringent, and the government is offering generous tax incentives for overseas investors, increasing the nation’s attractiveness.
Within the emerging regions, the majority of clinical trials in progress are for oncology, cardiovascular and metabolic conditions, and Alzheimer’s disease. The bulk of phase II and III clinical trials underway worldwide are being conducted in the emerging markets.
Nearly twenty key players in the world clinical trials sector are profiled within the report, such as: Chiltern, PPD, Kendle, Parexel, Pharmaceutical Product Development Inc, Covance Inc and Icon.
The 281 page report, published in September 2011 considers the global clinical trial market for the period 2007-2010. The global clinical trial market research report contains numerous charts and tables, coupled with detailed commentary to provide the reader with an in-depth understanding of the market. The market is discussed at length, including analysis of clinical trials by phase, by condition and geography.
Report Details: